MAP1LC3A Polyclonal Antibody

RAW264.7 cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 0.1% PBST for 20 min at room temperature, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with MAP1LC3A Polyclonal Antibody(bs-1534R)at 1:50 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).

Applications

WB
FCM
IHC-P
IF(IHC-P)

Reactivity

Human
Mouse

Predicted Reactivity

Rat
Cow
Pig
Chicken

Overview
Catalog #	bs-1534R
Product Name	MAP1LC3A Polyclonal Antibody
Applications	WB, FCM, IHC-P, IF(IHC-P)
Reactivity	Human, Mouse
Predicted Reactivity	Rat, Cow, Pig, Chicken
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human MAP1LC3A/MAP1A/MAP LC3 Alpha/Beta
Clonality	Polyclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	84557
Synonyms	MAP1LC3A; MAP1a + MAP1b; microtubule-associated protein 1 light chain 3; Autophagy LC3; Microtubule-associated proteins 1A/1B light chain 3A; MAPLC3; MAP-LC3; Microtubule-associated protein 1 light chain 3 alpha; MAP1A/1B light chain 3 A; MAP1A/MAP1B LC3 A; Autophagy-related protein LC3 A; Autophagy-related ubiquitin-like modier LC3 A; MAP1 light chain 3-like protein 1.MAP1LC3A
Background	Microtubule-associated MAPILC3A constitutes nearly half of the mass of all the microtubule associated proteins that copurify with brain microtubules. MAP1LC3A is one of three human orthologs of the rat Map1LC3, (named MAP1LC3A, MAP1LC3B, and MAP1LC3C). The three isoforms of human MAP1LC3 exhibit distinct expression patterns in different human tissues and also differ in their post-translation modifications. MAP1LC3A and MAP1LC3C are produced by the proteolytic cleavage after the conserved C-terminal Gly residue; MAP1LC3B does not undergo C-terminal cleavage and exists in a single modified form.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200